The Republic of Korea has supported the Global Fund since its creation, with a total contribution of US$84.82 million (KRW 8.34 billion) to date.
At the Seventh Replenishment conference, the Republic of Korea announced a a pledge amounting to US$100 million for the period 2023-2025. This pledge is the highest pledge ever announced by the Republic of Korea and represents a fourfold increase from its Sixth Replenishment pledge of US$25 million, covering 2020-2022.
The Republic of Korea’s substantial pledge to the Global Fund demonstrates its commitment to global health, to the fight against HIV, TB and malaria and its support for resilient and sustainable systems for health.
The Republic of Korea is not only a longstanding ally to the Global Fund, but also a major procurement partner, representing one of the largest suppliers of essential health commodities, in particular diagnostic tests.
Data updated on: 14 September 2023
South Korea’s contributions to the Global Fund are raised through an air ticket solidarity levy that finances the country’s Global Disease Eradication Fund. The Korean government introduced the levy in 2007, becoming one of the few G20 countries spearheading international efforts to create innovative solutions to raise resources for development.
Global health is a growing priority for South Korea’s international cooperation agenda. The Covid-19 pandemic has shed light on the “South Korean model” of pandemic response, providing opportunities for increased leadership in global health and health diplomacy. South Korea emphasizes the importance of health as a human right and an essential factor for socio-economic development, with a particular focus on equitable access to global public goods.
South Korea joined the Global Fund Board in 2018, assuming the seat that represents the Additional Public Donors constituency.
South Korea is the sixth largest supplier of essential health products to the Global Fund and the third largest supplier of diagnostic tests. Between 2008 and 2019, South Korea has provided over US $295 million worth of products, among which about 80% are diagnostic tests.
Republic of Korea Reaffirms Its Commitment to the Fight Against TB and Malaria
Global Fund Receives Top Marks in Performance Review
MCM Joins Partnership to Support Global Health
Republic of Korea Boosts Contribution to Global Fund